Katie E. Blise

A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway

The paper identifies resistance mechanisms to KRAS-MEK pathway targeting in PDAC by analyzing clinical trial data and multi-omics profiles, showing that KRAS/MYC co-gain correlates with resistance and that co-targeting these genes is synergistic.

Post-transcriptional regulator HuR promotes immune evasion in pancreatic ductal adenocarcinoma

This study shows that HuR promotes immune evasion in PDAC by inhibiting T cell infiltration and function, suggesting HuR as a therapeutic target with immunotherapy.

Tumor-intrinsic MHC-II activation in pancreatic ductal adenocarcinoma enhances immune response and treatment efficacy

This study shows that MHC-II expression in pancreatic cancer cells correlates with immune infiltration and improves immunotherapy response in mouse models.

Myc and Kras cooperate in adult acinar cells to drive phenotypic heterogeneity, metastasis, and therapeutic resistance in a novel pancreatic cancer mouse model

This study develops a novel pancreatic cancer mouse model by expressing Myc and mutant Kras in adult acinar cells, showing metastasis and therapeutic resistance similar to human PDAc.